Cite
HARVARD Citation
Claramunt García, R. et al. (n.d.). 2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia. European journal of hospital pharmacy. p. A10. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Claramunt García, R. et al. (n.d.). 2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia. European journal of hospital pharmacy. p. A10. [Online].